Shares in Danish drugmaker surge on positive signal from results
German biotech is shifting towards cancer treatments
Scientists have used the technology to model the behaviour of protein molecules
Big Four accountancy balks at high cost of medication it says has become ‘cultural phenomenon’
First-quarter sales of medication Zepbound increased 80% to $4.2bn
Drugmaker is looking to see which of its pipeline of drugs can be pushed forward while also trying to buy time
Resumption of £300mn in UK projects is a result of trade deal with US that aims to increase medicines spending
Resolution will allow billions of dollars to flow to US cities and states that have been hit by the epidemic
Swiss pharma group blames competition from generic medicines for 12% drop in first-quarter profit
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
Drugs developed in Asian nation are increasingly being used to seed US start-ups
Shares in US healthcare group jump as it steadies itself after turbulent period that led to departure of previous CEO
Stock in UK-based Compass Pathways jumps to highest level in two years following president’s executive order
Consumers await cheaper generics after expiry of patent for Ozempic ingredient
The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale
The ecommerce giant has agreed an $11.6bn deal to acquire satellite group Globalstar
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
And the US might find them hard to give up
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Recent setbacks for the movement signal a potential turning point for the vaccine makers as the market picks up
White House also rolls back levies on some metals in an attempt to simplify duties
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
